Details of the Drug-Related molecule(s) Interaction Atlas

Clorindione Drug Info

Chlophenadione; Chlor-athrombon; Chlorindione; Chlorindionum; Clorindiona [INN-Spanish]; Clorindione; Clorindione [INN:BAN]; Clorindionum [INN-Latin]; Indaliton; M.G. 2552; 1,3-Indandione, 2-(p-chlorophenyl)-; 1146-99-2; 2-(4-CHLOROPHENYL)INDANE-1,3-DIONE; 2-(4-Chlorophenyl)-1H-indene-1,3(2H)-dione; 2-(4-Chlorophenyl)indan-1,3-dione; 2-(4-chlorophenyl)indene-1,3-dione; 2-(p-Chlorophenyl)-1,3-indandione; 2-(p-Chlorophenyl)indan-1,3-dione; BRN 2052412; CHEMBL278519; EINECS 214-553-2; G 25766; G-25766; UNII-541C7WS64R

Cross-matching ID

PubChem CID

70846

ChEBI ID

CHEBI:135057

CAS Number

CAS 1146-99-2

TTD Drug ID

DMLPXNC

INTEDE Drug ID

DR0359

General Information of Drug (ID: DMLPXNC)

Molecule-Related Drug Atlas

Molecule Type:

DME

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[2]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[3]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[4]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[5]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[6]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[7]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[8]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[9]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[3]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)^{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[1]

------------------------------------------------------------------------------------

References

1	CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011 Jun;39(6):1039-46.
2	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
3	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
4	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
5	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
6	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
8	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
9	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
10	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.